In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors

被引:0
|
作者
Maulana, Saipul [1 ]
Wahyuni, Tutik Sri [1 ,2 ]
Widiyanti, Prihartini [3 ,4 ]
Zubair, Muhammad Sulaiman [5 ]
机构
[1] Univ Airlangga, Dept Pharmaceut Sci, Fac Pharm, Surabaya, Indonesia
[2] Univ Airlangga, Inst Trop Dis, Ctr Nat Prod Med Res & Dev, Surabaya, Indonesia
[3] Univ Airlangga, Fac Sci & Technol, Biomed Engn, Surabaya, Indonesia
[4] Univ Airlangga, Inst Trop Dis ITD, Surabaya, Indonesia
[5] Univ Tadulako, Dept Pharm, Fac Sci, Palu, Indonesia
关键词
Begonia; SARS-CoV-2; 3-Chymotrypsin-Like protease (3Clpro); Molecular docking; Molecular dynamics; CYTOTOXIC ACTIVITY; DOCKING; VALIDATION; DYNAMICS;
D O I
10.4081/jphia.2023.2508
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The emergence of Coronavirus disease (COVID-19) has been declared a pandemic and made a medical emergency worldwide. Various attempts have been made, including optimizing effective treatments against the disease or developing a vaccine. Since the SARS-CoV-2 protease crystal structure has been discovered, searching for its inhibitors by in silico technique becomes possible. Objective: This study aims to virtually screen the potential of phytoconstituents from the Begonia genus as 3Cl pro-SARS-CoV2 inhibitors, based on its crucial role in viral replication, hence making these proteases "promising" for the anti-SARS-CoV-2 target. Methods: In silico screening was carried out by molecular docking on the web-based program DockThor and validated by a retrospective method. Predictive binding affinity (Dock Score) was used for scoring the compounds. Further molecular dynamics on Desmond was performed to assess the complex stability. Results: Virtual screening protocol was valid with the area under curve value 0.913. Molecular docking revealed only beta-sitosterol-3-O-beta-D-glucopyranoside with a lower docking score of 9.712 kcal/mol than positive control of indinavir. The molecular dynamic study showed that the compound was stable for the first 30 ns simulations time with Root Mean Square Deviation <3 angstrom, despite minor fluctuations observed at the end of simulation times. Root Mean Square Fluctuation of catalytic sites HIS41 and CYS145 was 0.756 A and 0.773 angstrom, respectively. Conclusions: This result suggests that beta-sitosterol-3-O-beta-Dglucopyranoside might be a prospective metabolite compound that can be developed as anti-SARS-CoV-2.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Virtual Screening of Chinese Medicine Small Molecule Compounds Targeting SARS-CoV-2 3CL Protease (3CL pro)
    He, Qingxiu
    Chen, Xin
    Yang, Xi
    Li, Guangpin
    Gu, Haiqiong
    Chu, Han
    Lin, Zhihua
    Wang, Yuanqiang
    LETTERS IN DRUG DESIGN & DISCOVERY, 2021, 18 (04) : 355 - 364
  • [2] In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease
    Xiong, Muya
    Nie, Tianqing
    Shao, Qiang
    Li, Minjun
    Su, Haixia
    Xu, Yechun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 231
  • [3] In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease
    Zeyaullah, Md. M.
    Khan, Nida
    Muzammil, Khursheed
    AlShahrani, Abdullah
    Khan, Mohammad Suhail
    Alam, Md. Shane A.
    Ahmad, Razi A.
    Khan, Wajihul Hasan A.
    PLOS ONE, 2023, 18 (04):
  • [4] Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
    Bai, Bing
    Arutyunova, Elena
    Khan, Muhammad Bashir
    Lu, Jimmy
    Joyce, Michael A.
    Saffran, Holly A.
    Shields, Justin A.
    Kandadai, Appan Srinivas
    Belovodskiy, Alexandr
    Hena, Mostofa
    Vuong, Wayne
    Lamer, Tess
    Young, Howard S.
    Vederas, John C.
    Tyrrell, D. Lorne
    Lemieux, M. Joanne
    Nieman, James A.
    RSC MEDICINAL CHEMISTRY, 2021, 12 (10): : 1722 - 1730
  • [5] Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
    Sho Iketani
    Farhad Forouhar
    Hengrui Liu
    Seo Jung Hong
    Fang-Yu Lin
    Manoj S. Nair
    Arie Zask
    Yaoxing Huang
    Li Xing
    Brent R. Stockwell
    Alejandro Chavez
    David D. Ho
    Nature Communications, 12
  • [6] Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
    Zhu, Wei
    Xu, Miao
    Chen, Catherine Z.
    Guo, Hui
    Shen, Min
    Hu, Xin
    Shinn, Paul
    Klumpp-Thomas, Carleen
    Michael, Samuel G.
    Zheng, Wei
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (05) : 1008 - 1016
  • [7] The Interaction of Antiviral Drugs with SARS-Cov-2 3CL Protease
    Saadh, Mohamed J.
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 (03) : 865 - 868
  • [8] Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
    Niesor, Eric J.
    Boivin, Guy
    Rheaume, Eric
    Shi, Rong
    Lavoie, Veronique
    Goyette, Nathalie
    Picard, Marie-Eve
    Perez, Anne
    Laghrissi-Thode, Fouzia
    Tardif, Jean-Claude
    ACS OMEGA, 2021, 6 (25): : 16584 - 16591
  • [9] Capillary electrokinetic chromatography for chiral separation of potential SARS-CoV-2 3CL protease inhibitors
    Brier, Lucile
    Furman, Christophe
    Charton, Julie
    Deprez, Benoit
    Lipka, Emmanuelle
    ELECTROPHORESIS, 2024, 45 (11-12) : 1010 - 1017
  • [10] Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors (vol 12, 2016, 2021)
    Iketani, Sho
    Forouhar, Farhad
    Liu, Hengrui
    Hong, Seo Jung
    Lin, Fang-Yu
    Nair, Manoj S.
    Zask, Arie
    Huang, Yaoxing
    Xing, Li
    Stockwell, Brent R.
    Chavez, Alejandro
    Ho, David D.
    NATURE COMMUNICATIONS, 2021, 12 (01)